BENZENO SHARON

Chief Commercial Ofc Imm Med

BENZENO SHARON has filed 5 SEC Form 4 filings (23 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jun 30, 2026.

On the most recent filing, BENZENO SHARON is listed as Chief Commercial Ofc Imm Med at Adaptive Biotechnologies Corp. Inside the rolling window, BENZENO SHARON reported no open-market purchases and 6 open-market sales totaling $14.7M in ADPT. The largest disclosed transaction in the window is a sale of 308,477 ADPT shares on Nov 21, 2025, worth $5.2M.

Companies traded

Other insiders at ADPT

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$14.7M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ADPTSale$232KJun 30SEC ↗
ADPTSale$3.3MJun 30SEC ↗
ADPTSale$831KMar 13SEC ↗
ADPTSale$212KDec 8SEC ↗
ADPTSale$4.9MNov 24SEC ↗
ADPTSale$5.2MNov 24SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has BENZENO SHARON made?

BENZENO SHARON has filed 5 SEC Form 4 filings (23 transaction rows) across 1 company since 2025.

Which companies does BENZENO SHARON trade?

BENZENO SHARON has filed SEC Form 4 disclosures for 1 company, including ADPT.

When was BENZENO SHARON's most recent SEC Form 4 filing?

BENZENO SHARON's most recent SEC Form 4 filing on Tracefour is dated Jun 30, 2026.

What is BENZENO SHARON's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, BENZENO SHARON is listed as Chief Commercial Ofc Imm Med.

What is BENZENO SHARON's total buy and sell value in the current window?

Inside the rolling retention window, BENZENO SHARON bought $0 and sold $14.7M based on SEC Form 4 filings.

What was BENZENO SHARON's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 308,477 ADPT shares on 2025-11-21, worth $5.2M, per SEC Form 4 filings.